Horm Metab Res 2003; 35(11/12): 816-821
DOI: 10.1055/s-2004-814163
Original
© Georg Thieme Verlag Stuttgart · New York

Increased Activity of Catalase in Tumor Cells Overexpressing IGFBP-2

A.  Hoeflich1 , O.  Fettscher1 , G.  Preta2 , H.  Lahm1 , H.  J.  Kolb3 , E.  Wolf1 , M.  M.  Weber4
  • 1Lehrstuhl für Molekulare Tierzucht und Biotechnologie/Genzentrum, Ludwig-Maximilians-Universität, Munich, Germany
  • 2Department of Biochemistry and Molecular Biology, University of Ferrara, Ferrara, Italy
  • 3Institut für Klinische Chemie, Städtisches Krankenhaus München-Harlaching, Munich, Germany
  • 4Schwerpunkt Endokrinologie und Stoffwechselerkrankungen, I. Medizinische Klinik und Poliklinik, Johannes-Gutenberg-Universität, Mainz, Germany
Further Information

Publication History

Received 20 August 2003

Accepted after Revision 23 September 2003

Publication Date:
07 January 2004 (online)

Abstract

Elevated levels of IGFBP-2 are found in serum and tissues under various stressful conditions and in many malignancies. In previous studies, we have shown that overexpression of IGFBP-2 results in increased tumorigenic potential in Y-1 mouse adrenocortical tumor cells, and that these effects are presumably mediated through IGF-independent mechanisms. Here, we show that highly proliferative IGFBP-2-overexpressing Y-1 cells, but not control Y-1 cells, grow to very high cell densities. In order to evaluate whether the increased cell densities in IGFBP-2-transfected Y-1 cells were accompanied by alterations in the oxidative stress system, we analyzed the effect of IGFBP-2 overexpression on the activity of various antioxidative enzymes in two malignant cell lines. Among the tested antioxidative enzymes (catalase, superoxide-dismutase, glutathione peroxidase, glutathione S-transferase), only catalase enzyme activity was significantly higher in IGFBP-2-transfected Y-1 mouse adrenocortical tumor cells and in IGFBP-2-transfected human colon tumor cells (Caco-2) compared to control-transfected Y-1 and Caco-2 cells and non-tumor 293 human epithelial cells. However, overexpression of catalase in malignant cells did not result in increased resistance to oxidative stress as measured by cell viability and protein oxidation after treatment of the cells with hydrogen peroxide. This might be due to an upregulation of the GST enzyme activity after treatment with H2O2 that we observed selectively in the control-transfected Y-1 cells and which might compensate for the higher catalase activity in the IGFBP-2 overexpressing cells. In summary, we found a strong and selective upregulation of the catalase activity in IGFBP-2 overexpressing malignant Y-1 and Caco-2 cell lines that might contribute to the highly malignant phenotype of IGFBP-2 overexpressing tumors through as yet unknown mechanisms.

References

  • 1 Hoeflich A, Reisinger R, Lahm H, Kiess W, Blum W F, Kolb H J, Weber M M, Wolf E. Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter?.  Cancer Res. 2001;  61 8601-8610
  • 2 Wolf E, Lahm H, Wu M, Wanke R, Hoeflich A. Effects of IGFBP-2 overexpression in vitro and in vivo.  Pediatr Nephrol. 2000;  14 572-578
  • 3 Cazals V, Mouhieddine B, Maitre B, Le Bouc Y, Chadelat K, Brody J S, Clement A. Insulin-like growth factors, their binding proteins, and transforming growth factor-beta 1 in oxidant-arrested lung alveolar epithelial cells.  J Biol Chem. 1994;  269 14 111-14 117
  • 4 Besnard V, Corroyer S, Trugnan G, Chadelat K, Nabeyrat E, Cazals V, Clement A. Distinct patterns of insulin-like growth factor binding protein (IGFBP)-2 and IGFBP-3 expression in oxidant exposed lung epithelial cells.  Biochim Biophys Acta. 2001;  1538 47-58
  • 5 Cazals V, Nabeyrat E, Corroyer S, de Keyzer Y, Clement A. Role for NF-kappa B in mediating the effects of hyperoxia on IGF-binding protein 2 promoter activity in lung alveolar epithelial cells.  Biochim Biophys Acta. 1999;  1448 349-362
  • 6 Oberley T D, Oberley L W. Antioxidant enzyme levels in cancer.  Histol Histopathol. 1997;  12 525-535
  • 7 van Rossen M E, Sluiter W, Bonthuis F, Jeekel H, Marquet R L, van Eijck C H. Scavenging of reactive oxygen species leads to diminished peritoneal tumor recurrence.  Cancer Res. 2000;  60 5625-5629
  • 8 Lu Y P, Lou Y R, Yen P, Newmark H L, Mirochnitchenko O I, Inouye M, Huang M T. Enhanced skin carcinogenesis in transgenic mice with high expression of glutathione peroxidase or both glutathione peroxidase and superoxide dismutase.  Cancer Res. 1997;  57 1468-1474
  • 9 Sadani G R, Nadkarni G D. Role of tissue antioxidant defence in thyroid cancers.  Cancer Lett. 1996;  109 231-235
  • 10 Heck D E, Vetrano A M, Mariano T M, Laskin J D. UVB light stimulates production of reactive oxygen species: unexpected role for catalase.  J Biol Chem. 2003;  278 22 432-22 436
  • 11 Hoeflich A, Fettscher O, Lahm H, Blum W F, Kolb H J, Engelhardt D, Wolf E, Weber M M. Overexpression of insulin-like growth factor-binding protein-2 results in increased tumorigenic potential in Y-1 adrenocortical tumor cells.  Cancer Res. 2000;  60 834-838
  • 12 Höflich A, Lahm H, Blum W, Kolb H, Wolf E. Insulin-like growth factor-binding protein-2 inhibits proliferation of human embryonic kidney fibroblasts and of IGF-responsive colon carcinoma cell lines.  FEBS Lett. 1998;  434 329-334
  • 13 Borenfreund E, Puerner J A. Toxicity determined in vitro by morphological alterations and neutral red absorption.  Toxicol Lett. 1985;  24 119-124
  • 14 Aebi H. Catalase in vitro.  Methods Enzymol. 1984;  105 121-126
  • 15 Madesh M, Balasubramanian K A. Microtiter plate assay for superoxide dismutase using MTT reduction by superoxide.  Indian J Biochem Biophys. 1998;  35 184-188
  • 16 Habig W H, Pabst M J, Jakoby W B. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation.  J Biol Chem. 1974;  249 7130-7139
  • 17 Levine R L, Garland D, Oliver C N, Amici A, Climent I, Lenz A G, Ahn B W, Shaltiel S, Stadtman E R. Determination of carbonyl content in oxidatively modified proteins.  Methods Enzymol. 1990;  186 464-478
  • 18 Hoeflich A, Nedbal S, Blum W F, Erhard M, Lahm H, Brem G, Kolb H, Wanke R, Wolf E. Growth inhibition in giant growth hormone transgenic mice by overexpression of insulin-like growth factor-binding protein-2.  Endocrinology. 2001;  142 1889-1898
  • 19 Sander C S, Hamm F, Elsner P, Thiele J J. Oxidative stress in malignant melanoma and non-melanoma skin cancer.  Br J Dermatol. 2003;  148 913-922
  • 20 Cullen J J, Mitros F A, Oberley L W. Expression of antioxidant enzymes in diseases of the human pancreas: another link between chronic pancreatitis and pancreatic cancer.  Pancreas. 2003;  26 23-27
  • 21 Weydert C, Roling B, Liu J, Hinkhouse M M, Ritchie J M, Oberley L W, Cullen J J. Suppression of the malignant phenotype in human pancreatic cancer cells by the overexpression of manganese superoxide dismutase.  Mol Cancer Ther. 2003;  2 361-369
  • 22 Bilodeau J F, Patenaude A, Piedboeuf B, Carrier C, Petrov P, Faure R, Mirault M E. Glutathione peroxidase-1 expression enhances recovery of human breast carcinoma cells from hyperoxic cell cycle arrest.  Free Radic Biol Med. 2002;  33 1279-1289
  • 23 Brown-Borg H M, Rakoczy S G, Romanick M A, Kennedy M A. Effects of growth hormone and insulin-like growth factor-1 on hepatocyte antioxidative enzymes.  Exp Biol Med (Maywood ). 2002;  227 94-104
  • 24 Xie C, Lovell M A, Xiong S, Kindy M S, Guo J, Xie J, Amaranth V, Montine T J, Markesbery W R. Expression of glutathione-S-transferase isozyme in the SY5Y neuroblastoma cell line increases resistance to oxidative stress.  Free Radic Biol Med. 2001;  31 73-81
  • 25 Bai J, Cederbaum A I. Catalase protects HepG2 cells from apoptosis induced by DNA-damaging agents by accelerating the degradation of p53.  J Biol Chem. 2003;  278 4660-4667
  • 26 Tome M E, Baker A F, Powis G, Payne C M, Briehl M M. Catalase-overexpressing thymocytes are resistant to glucocorticoid-induced apoptosis and exhibit increased net tumor growth.  Cancer Res. 2001;  61 2766-2773
  • 27 Kim H S, Lee T B, Choi C H. Down-regulation of catalase gene expression in the doxorubicin-resistant AML subline AML-2/DX100.  Biochem Biophys Res Commun. 2001;  281 109-114
  • 28 Bubendorf L, Kolmer M, Kononen J, Koivisto P, Mousses S, Chen Y, Mahlamaki E, Schraml P, Moch H, Willi N, Elkahloun A G, Pretlow T G, Gasser T C, Mihatsch M J, Sauter G, Kallioniemi O P. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays.  J Natl Cancer Inst. 1999;  91 1758-1764
  • 29 Moore M G, Wetterau L A, Francis M J, Peehl D M, Cohen P. Novel stimulatory role for insulin-like growth factor binding protein-2 in prostate cancer cells.  Int J Cancer. 2003;  105 14-19

A. Hoeflich

Lehrstuhl für Molekulare Tierzucht und Biotechnologie, Ludwig-Maximilians-Universität ·

Feodor-Lynen-Straße 25 · 81377 München · Germany

Phone: + 49 (89) 21 80 76-815 ·

Fax: + 49 (89) 21 80 76-849

Email: hoeflich@lmb.uni-muenchen.de

    >